Get the Stockscreener App
15.66
6.03%
-1.10
Dyne Therapeutics Inc stock is traded at $15.66, with a volume of 263.89K.
It is down -6.03% in the last 24 hours and down -33.96% over the past month.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
See More
Previous Close:
$16.76
Open:
$16.75
24h Volume:
263.89K
Relative Volume:
0.16
Market Cap:
$1.71B
Revenue:
-
Net Income/Loss:
$-294.51M
P/E Ratio:
-4.3989
EPS:
-3.56
Net Cash Flow:
$-244.42M
1W Performance:
+10.76%
1M Performance:
-33.96%
6M Performance:
-62.67%
1Y Performance:
-26.54%
1-Day Range:
$15.66
$16.75
1-Week Range:
$13.36
$17.18
52-Week Range:
$13.23
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
15.69 | 1.71B | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.30 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.35 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
654.01 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
272.75 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.28 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by Jennison Associates LLC - MarketBeat
Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now - Insider Monkey
DYN Stock Sees Surge of Approximately 15.81% in Last Five Days - Knox Daily
Learn to Evaluate (DYN) using the Charts - Stock Traders Daily
Investor’s Delight: Dyne Therapeutics Inc (DYN) Closes Weak at 13.87, Down -2.46 - The Dwinnex
Dyne Therapeutics Inc’s results are impressive - US Post News
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
DYN (Dyne Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
Dyne Therapeutics Reveals Latest Developments at Major Healthcare ConferenceKey Updates Coming - StockTitan
Dyne Therapeutics, Inc. (DYN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Recent Analysts’ Ratings Changes for Dyne Therapeutics (DYN) - Defense World
Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround - MSN
Dyne Therapeutics (NASDAQ:DYN) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Dyne Therapeutics’ (DYN) Buy Rating Reiterated at Guggenheim - Defense World
Dyne Therapeutics' (DYN) Buy Rating Reiterated at Guggenheim - MarketBeat
(DYN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Dyne Therapeutics (NASDAQ:DYN) Hits New 52-Week LowTime to Sell? - MarketBeat
Dyne Therapeutics: Moving Forward On 2 Key Fronts - Seeking Alpha
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $49.91 Average Price Target from Analysts - MarketBeat
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Oppenheimer maintains Dyne stock Outperform with $60 target - MSN
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 - GlobeNewswire
Dyne stock gains on FDA fast track tag (DYN:NASDAQ) - Seeking Alpha
Dyne Enjoys Fast Track Status for New Treatment - Baystreet.ca
Dyne Therapeutics reports clinical data from its myotonic dystrophy type 1 treatment - MSN
JPMorgan Chase & Co. Grows Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics (NASDAQ:DYN) Hits New 1-Year Low – Here’s Why - Defense World
Dyne Therapeutics (NASDAQ:DYN) Shares Down 4.7%What's Next? - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Reaches New 1-Year LowWhat's Next? - MarketBeat
How To Trade (DYN) - Stock Traders Daily
Dyne Therapeutics' (DYN) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat
Dyne Therapeutics Provides Updates on Clinical Trials in Recent 8-K Filing - Defense World
Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week Low – Time to Sell? - Defense World
HC Wainwright Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN) - Defense World
Chardan Capital Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN) - Defense World
Dyne Therapeutics (NASDAQ:DYN) Reaches New 12-Month LowWhat's Next? - MarketBeat
Dyne Therapeutics stock tumbles following trial data By Investing.com - Investing.com Australia
Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potenti - Investing.com South Africa
Dyne Therapeutics (NASDAQ:DYN) Receives "Buy" Rating from Chardan Capital - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Earns "Buy" Rating from HC Wainwright - MarketBeat
Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday? - Benzinga
Dyne Therapeutics (NASDAQ:DYN) Shares Gap DownHere's Why - MarketBeat
Dyne Therapeutics stock tumbles following trial data - Investing.com
Why Dyne Therapeutics Shares Are Shifting - TipRanks
Dyne Therapeutics Advances Clinical Trials for DM1 and DMD - TipRanks
Dyne Therapeutics Reports New Clinical Data Showing - GlobeNewswire
Dyne Therapeutics' DM1 Treatment Shows Breakthrough Results, Plans Accelerated FDA Filing - StockTitan
Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Dyne Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET - The Manila Times
Dyne Therapeutics shares jump ahead of clinical data review By Investing.com - Investing.com Canada
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dyne Therapeutics Inc Stock (DYN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Scalzo Richard William | SVP, Head of Finance & Admin. |
Dec 11 '24 |
Sale |
28.12 |
1,455 |
40,915 |
127,078 |
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):